bioRxivPharmacology & Toxicology
Human engineered heart tissue transplantation in a guinea pig chronic injury model
C. von Bibra, A. Shibamiya, B. Geertz, E. Querdel, M. Koehne, T. Stuedemann, J. Starbatty, A. Hansen, B. Hiebl, T. Eschenhagen, F. Weinberger
Abstract
AO_SCPLOWBSTRACTC_SCPLOWMyocardial injury leads to an irreversible loss of cardiomyocytes (CM). The implantation of human engineered heart tissue (EHT) has become a promising regenerative approach. Previous studies exhibited beneficial, dose-dependent effects of human induced pluripotent stem cell (hiPSC)-derived EHT patch transplantation in a guinea pig model in the subacute phase of myocardial injury. Yet, advanced heart failure often results from a chronic remodeling process. Therefore, from a clinical standpoint it is worthwhile to explore the ability to repair the chronically injured heart. In this study human EHT patches were generated from hiPSC-derived CMs (15x106 cells) and implanted epicardially four weeks after injury in a guinea-pig cryo-injury model. Cardiac function was evaluated by echocardiography after a follow-up period of four weeks. Hearts revealed large transmural myocardial injuries amounting to 27% of the left ventricle. EHT recipient hearts demonstrated compact muscle islands of human origin in the scar region, as indicated by a positive staining for human Ku80 and dystrophin, remuscularizing 5% of the scar area. Echocardiographic analysis demonstrated no significant difference between animals that received EHT patches and animals in the control group (fractional area change 36% vs. 34%). Thus, EHT patches engrafted in the chronically injured heart but in contrast to the subacute model, grafts were smaller and EHT patch transplantation did not improve left ventricular function, highlighting the difficulties for a regenerative approach.
- organism: rat
- assay: imaging
- research focus: cell type annotation
- research focus: cell-cell communication
- research focus: trajectory inference
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immature human engineered heart tissues engraft in a guinea pig chronic injury model
C. von Bibra, A. Shibamiya, … F. Weinberger·bioRxiv·Jul 7, 2022
- In situ maturated early-stage human induced pluripotent stem cell-derived cardiomyocytes improve cardiac function by enhancing segmentary contraction in infarcted rats
D. Biagi, E. T. Fantozzi, … R. Dariolli·bioRxiv·Mar 9, 2021
- Evaluation of the Efficacy and Safety of a Clinical Grade Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Patch: A Pre-Clinical Study
S. Miyagawa, T. Kawamura, … Y. Sawa·bioRxiv·Apr 7, 2021
- Delta-1 functionalized hydrogel promotes hESC-cardiomyocyte graft proliferation and maintains heart function post-injury
K. A. Gerbin, K. A. Mitzelfelt, … C. E. Murry·bioRxiv·Sep 14, 2019
- PLURIPOTENT STEM CELL-DERIVED CARDIOVASCULAR PROGENITORS DIFFFERENTIATED ON LAMININ 221 REGENERATE AND IMPROVE FUNCTION OF INFARCTED SWINE HEARTS
L. Yap, L. Y. Chong, … K. Tryggvason·bioRxiv·Apr 29, 2021
- Human iPSC-derived Committed Cardiac Progenitors Generate Cardiac Tissue Grafts in a Swine Ischemic Cardiomyopathy Model without Triggering Ventricular Arrhythmias
A. N. Raval, E. G. Schmuck, … T. J. Kamp·bioRxiv·Feb 14, 2024